News

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...
etnet43m

{Hot Stocks}SIMCERE PHARMA quoted at HK$14.28, up 9.8%

ET Net News Agency, 29 July 2025] SIMCERE PHARMA (02096) rose 9.8% to HK$14.28. It hits an intra-day high of HK$14.28, hitting a historical high, and an intra-day low of HK$13.1. The total shares ...
BioSpace18h

GSK Bets Up To $12B for Multi-Program Cancer Pact With Hengrui

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...